OncologyEducation· @OncEd · X·· 15 小时前评分70
正文 · 机器翻译
FOURLIGHT-1 亮相 #ESMO26：atirmociclib + fulvestrant 在接受 CDK4/6 抑制剂治疗后的 HR+/HER2− mBC 中，较研究者选择方案延长了 PFS（中位 9.4 vs. 6.6 个月；HR 0.60）。Antonio Giordano, MD, PhD @antgiorda 进行解读。立即观看：https://bit.ly/4zPpSD5
13 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：OncologyEducation · x.com